Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.55 |
| ▸ | FNTA | P49354 | 8/20 | 0.53 |
| ▸ | FNTB | P49356 | 8/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316290 | 0.88 | CYP11B1 (0.48) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL28693185 | 0.86 | CYP11B1 (0.52) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL448443 | 0.85 | FNTA (0.54) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8142947 | 0.82 | CYP11B1 (0.47) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8142936 | 0.81 | FNTA (0.44) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8149667 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL5891899 | 0.80 | CYP11B1 (0.68) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3501862 | 0.80 | FNTA (0.59) | FNTAFNTBPGGT1BKCNH2 | |
| Hydrochloric Acid SCHEMBL8188315 | 0.79 | CYP11B1 (0.67) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL6981310 | 0.79 | HSP90AA1 (0.42) | CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | claimed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4552697-A2 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-3514151-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2022-04-14 | — | — | US | disclosed |
| CN-113214246-A | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20010044451-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| US-6313138-B1 | FOR THERAPY OF ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES IN MAMMALS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000053605-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP11B1 787/4885CYP11B2 887/4885FNTA 1583/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | CYP11B1 2889/4885CYP11B2 3250/4885FNTA 3317/4885 |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, PKM, PDK2 | CYP11B1 776/4885CYP11B2 769/4885FNTA 3930/4885 |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | CYP11B1 2665/4885CYP11B2 2891/4885FNTA 3572/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | CYP11B1 787/4885CYP11B2 887/4885FNTA 1583/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | CYP11B1 2889/4885CYP11B2 3250/4885FNTA 3317/4885 |
| US-20010044451-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CYP11B1 3248/4885CYP11B2 3772/4885FNTA 2966/4885 |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | CYP11B1 776/4885CYP11B2 769/4885FNTA 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.